Immitra Bio has secured €2.58 million in pre-Seed financing, its first external funding round, to advance its novel mutation-agnostic in-vivo gene editing platform. The round was led by Backbone Ventures and co-led by OCCIDENT, with participation from several other venture capital and private investors. These funds will enable Immitra Bio to achieve key value inflection points and establish itself as a leader in scalable, one-time curative gene editing therapies.